Moreover, a recent in vivo CRIPR-Cas9 screening in B16F10 cells highlighted the role of the histone methyltransferase SETDB1 in reducing the immunogenicity of murine melanoma cells, thus enhancing resistance to anti-PD-1 therapy (94). The gene discussed is PRDM9; the disease is melanoma.